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1) Introduction 
 
Schizophrenia is a heterogeneous disorder that affects 0.4% (McGrath et al., 2008) 
of the world population and has a broad range of symptoms. These include positive or 
psychotic symptoms (delusions, hallucination, bizarre behavior and formal thought 
disorder) (Tamminga, 2008), negative symptoms (such as affective flattening, alogia and 
avolition), disorganization of speech and behavior, affective symptoms (depression or 
mania) and cognitive impairment in various domains. Except for cognition, symptoms of 
schizophrenia are generally assessed by scales such as the Brief Psychiatric Rating Scale 
(BPRS) (Overall and Gorham, 1962), or the Positive and Negative Syndrome Scale 
(PANSS) (Kay et al., 1987). 
The majority of guidelines and algorithms for the treatment of schizophrenia agree 
that when patients do not respond to treatment with at least two different types of 
antipsychotic in monotherapy, with adequate doses of 4- to 6-week duration, they are 
considered to have Treatment-Resistant Schizophrenia (TRS) (Elkis, 2007) (Howes et al., 
2017). Although the true prevalence of TRS is unknown, it is generally estimated to 
account for 30-40% of patients with schizophrenia (Elkis and Buckley, 2016).  
Clozapine is the best treatment option for TRS compared to first- or second-
generation antipsychotics (Siskind et al., 2016), although its use varies considerably 
worldwide (Bachmann et al., 2017). However, there is no specific treatment, with a high 
level of evidence, which proved to be effective in patients with resistance to clozapine 
(Wagner et al., 2019) except perhaps for electroconvulsive therapy (Wang et al., 2018).  
It has been proposed that TRS may represent a  distinct category or subtype of 
schizophrenia (Gillespie et al., 2017) and a recent international consensus guideline has 
recommended that standardized, validated symptom rating scales such as the BPRS 
(Overall and Gorham, 1962) or the Positive and Negative Syndrome Scale (PANSS) (Kay 
et al., 1987) should be used in order to adequately measure symptom severity in TRS 
(Howes et al., 2017). 
In fact, the PANSS it is considered the worldwide gold standard for the 
measurement of symptoms of schizophrenia and it is composed of 30 items grouped in 
three subscales: Positive (P1 to P7), Negative (N1 to N7) and General Psychopathology 
(G1 to G16) (Kay et al., 1987).  
4 
 
 
However, factor analyses (FA) of the original 30 item PANSS items cluster in more 
than the three dimensions as for example, the four-factor model (‘Pyramidical’) (Kay and 
Sevy, 1990)  but, since the original five-factor model was published (Lindenmayer et al., 
1994), various models have been replicated showing that the PANSS has 5 factors 
domains namely Positive, Negative, Disorganization, Cognitive and Excitement. These 
models received different names across studies as is the case of  
 Further studies which received different denominations, as is the case the 
“Pentagonal model” (White et al., 1997) and the Marder model (Marder et al., 1997). 
Wallwork et al, using the vote counting method.  In terms of validity the National 
Institute of Mental Health’s (NIMH) model, which was obtained by consensus (Wallwork 
et al., 2012) has shown to have a good fit to the data when compared cross nationally 
(Stefanovics et al., 2014).   
However various PANSS factor analytical models have different number of factors, 
different numbers of items assigned to each factor and different goodness of fit index 
to the data (Lindenmayer, 2017), even when obtained from large samples such as the 
case of the  Van der Gaag model (VDAAG) (van der Gaag et al., 2006b) which may 
explained by the heterogeneity of methodological aspects of FA, such sample size, type 
of rotation employed, as well as ethnic and cultural differences (Stefanovics et al., 2014). 
The models are displayed in Table 1. 
However, to the best of our knowledge, there are no studies that used FA comparing 
patients with TRS with patients with NTRS. Two FA studies included patients with TRS, 
as it is the case of Lindenmayer’s et al (Lindenmayer et al., 2004), which investigated the 
symptom profile of 157 TRS patients assigned to clozapine or other antipsychotics, and 
the Woodward’s et al (Woodward et al., 2013), which compared patients with TRS with 
other types of diagnosis. Both studies found no substantial difference from models 
yielded as compared with the original PANSS five- factor model (Lindenmayer et al., 
1994).  
Thus, we think would be of clinical as well as heuristic value to compare two 
populations of patients with TRS with NTRS in terms of the factorial structure of the 
PANSS and therefore, aim of the present study is to use Exploratory Factor Analysis (EFA) 
to investigate whether patients with TRS have a distinct PANSS factor structure when 
compared with patients with NTRS. For this, we used data from the cross-sectional 
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phase of the Pattern study -an international, multicenter, non-interventional, 
prospective, cohort study with 1429 subjects (Haro et al., 2015).  
 
The secondary aim of the study is to use Confirmatory Factor Analysis (CFA) to test 
the fit of the factorial structures found in the present study in comparison with well-
established PANSS factor models, namely: “Original” (three- factor)(Kay et al., 1987), 
“Pyramidical “ ( four-factor)(Kay and Sevy, 1990), “Pentagonal” ( five- factor), the “NIMH” 
or consensus model ( five-factor) (White et al., 1997),  VGAAG or van de Gaag’s model              
(five-factor) (van der Gaag et al., 2006b), and a TRS model (Lindenmayer) (Lindenmayer 
et al., 1994) which has a similar structure to the original five-factor model (Lindenmayer 
et al., 1994). 
 
 
2)  Material and Methods 
 
2.1.) Population: The Pattern study 
 
Data from this work were drawn from the Pattern study, an international, 
multicenter, non-interventional (observational), prospective study sponsored by Roche. 
It aimed to investigate the impact of persistent symptoms on the course and burden of 
illness in outpatients with schizophrenia attending psychiatric centers in eight countries. 
The Pattern study had two phases: 
1-The cross-sectional phase that constituted a baseline observation for the 
longitudinal phase; 
2-The longitudinal phase that consisted of a 24-month follow-up to collect data 
from all patients who were not in recovery at the baseline assessment. 
Patients met the inclusion criteria for the baseline phase if they had a diagnosis of 
schizophrenia according to the DSM IV TR or ICD 10, were aged 18 years or older, were 
in a stable condition without recent acute relapse (within last three months), and were 
able to give informed consent and willing to comply with study protocol. The exclusion 
criteria for the baseline phase were: an acute psychotic exacerbation in the 3 months 
before the baseline observation, concurrent enrollment in an interventional study at the 
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time of baseline observation, or being unable or unwilling to comply with the study 
(Haro et al., 2015). In order to maximize the generalizability of the study findings, no 
entry criteria were applied regardless treatment history, comorbidity or history of 
substance abuse (Sheehan et al., 1998).  
For the longitudinal phase, similar criteria were applied, with the additional 
exclusion of patients found to be in a clinical recovery:  both PANSS positive and negative 
subscales fewer than 28 points. Data from this phase of the Pattern study have been 
recently published (Haro et al., 2018) but were not included in the present analysis.  
Volunteer patients were recruited from 140 centers across eight countries 
(Argentina, Brazil, Canada, France, Germany, Italy, Spain and the United Kingdom) and 
provided informed consent. All local internal review boards approved the Pattern study 
as well as the present investigation; it was approved by the University of São Paulo 
General Hospital internal review board (Protocol number 1.788.340). Further details of 
the Pattern study are available in Haro et al. (Haro et al., 2015). 
Clinical assessment and patient-reported outcome (PRO) data were captured using 
a hand-held electronic tablet. Trained professionals used the device, as well as the 
patients and their family or informal care takers. 
Psychiatrists captured data produced by assessment with clinical rating scales, while 
patients captured PRO questionnaire data independently at the clinic. The assessment 
by the participating psychiatrists included socio-demographic and clinical variables using 
the Positive and Negative Syndrome Scale (PANSS) (Kay et al., 1987), the Clinical Global 
Impression for Schizophrenia (CGI) (Haro et al., 2003) and Personal and Social 
Performance Scale (PSP) (Morosini et al., 2000).  
A total of 1,429 patients were recruited in 8 countries (Argentina N=110, Brazil 
N=100, Canada N=117, France N=237, Germany N=250, Italy N=219, Spain N=207, and 
the United Kingdom N=139). Socio-demographic information was similar across 
countries. Most patients (70.56%) were male, and the mean age was 42.1 years.  
Fourteen percent of the patients had at least one psychiatric co-morbidity, and 35% had 
experienced a substance use problem. The mean total PANSS score was 77.98 points. 
Regarding medication treatment, 98% of patients were using antipsychotics, and 
31% were on combination regimens. Clozapine was the most frequently prescribed 
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antipsychotic (29%) followed by risperidone (22%), olanzapine (16%) and aripiprazole 
(15%) (Haro et al., 2015). 
 
2.2) Study Data 
 
We analyzed data derived exclusively from the cross-sectional phase of the Pattern 
study.  The original protocol of the study defines TRS according to two criteria:  
 
• Definition 1: “patients who have been treated with clozapine at any time over 
the previous year as indicated by the treating psychiatrist”  
 
• Definition 2: “patients who, in the opinion of the investigator, have been 
treatment resistant at any time during the previous year according to the 
standard definition of failing to respond to two or more adequate trials of 
medication”.  
 
However, this second definition is problematic. A recent authoritative review of 
response and resistance in schizophrenia established minimum requirements for the 
definition of TRS that include an adequate assessment of present and past response to 
treatment using validated instruments, as well as evaluation of factors that may 
interfere with response e.g., adherence to treatment (Howes et al., 2017). Since the 
Pattern study was non-interventional, prospective evaluation of adequate response to 
treatment or adherence was not possible, thus compromising the definition of TRS 
exclusively based on clinician judgment of past response to treatment.  
Therefore, in the present study, the definition of TRS based on current use of 
clozapine was adopted. It is well established that this medication is the drug of choice in 
TRS (Elkis and Buckley, 2016) (Howes et al., 2017).  Consequently, those patients taking 
non-clozapine antipsychotics were defined as NTRS.  
 
2.2.1) Statistical analysis 
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The analyses included all patients who fulfilled the eligibility criteria for the cross-
sectional phase (N=1,429).  Demographic variables were compared between both 
groups using t-test or chi-squared techniques. 
EFA was based on the extraction of a principal component analysis (PCA) using the 
varimax orthogonal rotation for all PANSS items. We chose the number of factors 
according to the Kaiser criteria (‘eigenvalue’ equal to or greater than 1). The Kaiser-
Meyer-Olkin and Bartlett's test of sphericity were used to measure the adequacy of the 
sample. Loadings equal to or greater than 0.5 were used to define factors.  
CFA is an appropriate method to confirm the dimensions of latent structures as well 
as to evaluate the fit to the data. CFA starts from a previous theoretical solution defined 
by the researchers; it tests whether a hypothetical latent structure is consistent or 
inconsistent with the empirical data using structural equation models (SEM) 
(Schumacker and Lomax, 1996). 
The fit of data to the models uses robust weighted least squares estimators under 
the polychoric correlation matrix. The following goodness-of-fit indexes were used: Chi-
square, Comparative Fit Index (CFI), Non-Normed Fit Index (TLI/NNFI) and the Root 
Mean Squared Error of Approximation (RMSEA) (Schreiber et al., 2006). 
 The following models were tested: the model obtained in the present study using 
EFA (´Present model´), the original three dimensional PANSS model (‘Original’) (Kay et 
al., 1987) , the four-factor model (‘Pyramidical’) (Kay and Sevy, 1990), the ‘pentagonal’ 
five-factor model (‘Pentagonal’)(White et al., 1997), the model obtained by 
Lindenmayer et al. using TRS patients (‘Lindenmayer’) (Lindenmayer et al., 2004) as well 
as models obtained by consensus or large samples such as the Van der Gaag model 
(‘VDGAAG’) (van der Gaag et al., 2006b) and the National Institute of Mental Health 
(‘NIMH’) model (Wallwork et al., 2012). These models are described in Table 1.  
Statistical analyses were conducted using SPSS 23.0 and the R program version 
3.2.2. 
 
 
2) Results 
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Table 2 presents the relationship between the two definitions of treatment resistance 
used in the Pattern study, namely: use of clozapine in the previous year (definition 1), 
or failure to respond to two antipsychotic treatments during the previous year 
(definition 2).  The agreement was highly significant (p=0.0001) with only 6.4% of 
patients who fulfilled definition 2 not meeting definition 1. The demographic 
characteristics of the sample are presented in Table 3. 
 
3.1) Exploratory factor analysis 
 
A principal component analysis (PCA) was performed for the PANSS in TRS and NTRS 
patients to differentiate subsyndromes. Before performing PCA, the suitability of the 
data for factor analysis was checked in the TRS and NTRS samples; the Kaiser-Meyer 
Olkin values were 0.928 and 0.944 respectively, exceeding the recommended value of 
0.6. Bartlett´s test of sphericity, which indicates the correlation among items, was 
sufficiently large, supporting the factorability of the correlation matrix (See 
Supplementary Material). 
In patients with TRS, an evaluation of the Scree plot and eigenvalue criteria 
(exceeding one) indicated five distinct and interpretable factors. After 
performing varimax rotation, a five-factor model was obtained, accounting for 57.37% 
of the variance (See Supplementary Material). 
In this analysis, the factor with the highest loadings (Factor 1) was the Negative 
Factor, composed of items N1+N2+N3+N4+N6+G7+G16. It explained 17.74% of the 
variance. The second factor was the Positive Factor (Factor 2) that explained 11.31% of 
the variance and was composed the following items: P1+P3+P5+P6+G9. The third factor 
was named “Anxiety/Depression” (Factor 3); it was formed of G2+G3+G4+G6 and 
explained 10.34% of the variance. The fourth factor, designated “Cognitive” (Factor 4), 
explained 9.28% of the variance and was composed of the P2+N5+N7+G5 items.  Finally, 
the items P7+G8+G14 formed the Excited Factor (Factor 5), that explained 8.70% of the 
variance. The rotated factor structure is presented in Table 4. 
In patients with NTRS, an evaluation of the Scree plot and eigenvalue criteria 
(exceeding one) converged on a five-factor solution. Varimax rotation evidenced the 
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same five factors; these accounted for 60.62% of the variance (See Supplementary 
Material).  
The factor with the highest loadings (Factor 1) was the Negative Factor, formed by 
the items N1+N2+N3+N4+N6+G7+G16. It explained 17.41% of the variance. The second 
factor was the Positive Factor (Factor 2), composed of P1+P3+P5+P6+G9, explaining 
12.53% of the variance. The third, Anxiety/Depression Factor (Factor 3), explained 
11.77% of the variance and consisted of G1+G2+G3+G4+G6 items. The fourth, Cognitive 
Factor (Factor 4), was composed of P2+N5+G5+G11 and explained 10.39% of the 
variance. Finally, the Excitement Factor (Factor 5) was represented by P7+G8+G14 and 
explained 8.52% of the variance (Table 4).  
The two models (TRS and NTRS) differed in the composition of the 
Anxiety/Depression and Cognitive factors. In the TRS-model, the Anxiety/Depression 
Factor did not include the G1 item, and the Cognitive factor included the N7, but not the 
G11 item. 
The following items, in NTRS patients, did not load onto any Factor: P4, N7, G10, 
G12, G13 and G15. In TRS patients the factors that did not load were P4, G1, G10, G11, 
G13 and G15. 
 
3.2) Confirmatory factor analysis 
 
The six models exhibited significant results in both samples (TRS and NTRS). 
Although a good model fit would be indicated by a non-significant χ2 result, this test is 
known to be highly sensitive to sample size and variable distribution.  For any hypothesis 
testing, a large sample size increases the probability of better estimates and reduces the 
probability of small errors; thus, increasing the chances of identifying proposed 
underlying latent models.  
Therefore, we used several additional absolute and incremental indices to evaluate 
the goodness of fit. Two indexes were used in combination: the Comparative Fit Index 
(CFI) and the Root Mean Square Error of Approximation (RMSEA). The CFI should be 0.9 
or higher, and the RMSEA should be 0.06 or lower (Bentler and Yuan, 1999) (Marsh et 
al., 2004). The results of the CFA for the previously published models are presented in 
Table 5.  
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In comparison with previous models for patients with TRS, the Present model 
showed a better fit to the data when compared with the Original, Pyramidical and NIMH 
models, and a worse fit when compared with the Lindenmayer, VDAAG and Pentagonal 
models. For NTRS patients, the Present model showed the second best fit to data: the 
VDAAG and Pentagonal models had the same fit and were superior to the Present 
model.  
 In the case of TRS patients, the VDGAAG model, regarded as the best model, 
achieved the best fit to the data, whereas the Pentagonal and VDAAG model showed a 
better fit in NTRS patients. In addition, in the TRS sample, Lindenmayer’s model had a 
good fit when compared with the VDGAAG model.  All the CFI values reached 0.90 or 
higher and none of the RSMEA reached 0.06 or lower. Therefore, none of the models 
achieved a perfect fit. 
 
4) Discussion 
 
To the best of our knowledge, this is the first study to investigate PANSS dimensions 
comparing TRS and NTRS patients, using both EFA and CFA, in a large population of 
patients with schizophrenia. The main finding of the present study was that the factorial 
structure of the PANSS was almost identical in patients with TRS and those with NTRS. 
     Additional findings were that patients with TRS had a significantly greater mean age 
of onset, duration of illness, PANSS positive score and duration of persistent negative 
and positive symptoms. There was no difference in the duration of untreated psychosis. 
These findings are in accordance with previous studies that have compared TRS with 
NTRS (Elkis and Buckley, 2016) (Meltzer et al., 1997) (Lançon et al., 2000) (Henna Neto 
and Elkis, 2007) (Werneck et al., 2011) (Altamura et al., 2007). However, NTRS patients 
had a significantly higher number of previous suicide attempts, and substance 
abuse/dependence was more frequent amongst these patients. There was no difference 
in the number of hospitalizations, contrasting with previous studies from our group 
(Alves et al., 2005). 
The results of the EFA in TRS and NTRS patients replicate earlier factor analytic 
studies that found a PANSS five-factor structure composed of Negative, Positive, 
Affective, Cognitive and Excitement dimensions. Additionally, our results replicated 
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other studies that found an important internal consistency of the Negative factor 
(Lançon et al., 2000), in both TRS and NTRS patients. 
The use of CFA to compare the factorial structure obtained in the present study with 
other established PANSS models showed that neither TRS nor NTRS groups obtained a 
very good fit. Some models may be considered to have a better fit; namely, the 
Pentagonal model for the NTRS, the Lindenmayer model for the TRS group and the 
VDGAAG model for both groups. 
These results are similar to findings from Lindenmayer et al. (Lindenmayer et al., 
2004) who conducted an EFA of PANSS dimensions and found no difference between 
TRS and NTRS patients.  
The superiority of the VDGAAG model compared to other models is explained by its 
larger sample size (5769 subjects), despite this, it could not distinguish TRS from NTRS. 
It is of note that although the study by Lindenmayer et al. had only 157 subjects, the 
PANSS factorial model they obtained achieved a very good fit (Stefanovics et al., 2014).  
It seems that a perfect fit to the data is rarely achieved either in systematic 
reviews studies of the PANSS (van der Gaag et al., 2006a) or cross-national studies 
(Stefanovics et al., 2014). In the case of the present study it may be explained by the 
clinical heterogeneity of schizophrenia as well as methodological bias introduced by 
having multiple interviewers from various centers in different countries, with no 
evaluation of PANSS inter-rater reliability among them. 
 
 
4.2) Strengths 
 
It is assumed that TRS makes up at least 30% of the population with schizophrenia 
(Kane et al., 1988). However, as identified in a recent study, the definition of TRS is very 
heterogeneous, and its prevalence may be even higher. Indeed, this heterogeneity of 
definition means the exact prevalence of TRS in patients with schizophrenia is unknown 
(Howes et al., 2017).  
 The validity of defining TRS ‘by proxy’, based on the use of clozapine in the previous 
year, is supported by the fact that patients labeled as TRS (or NTRS) in this study showed 
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demographic and clinical features consistent with previous descriptions of these 
syndromes. In the present study, patients with TRS showed an earlier age of onset, a 
longer duration of illness and a male predominance (Table 3). These characteristics have 
been observed in previous studies that adequately distinguished patients with TRS from 
those with NTRS (Meltzer et al., 1997) (Henna Neto and Elkis, 2007) (Werneck et al., 
2011). 
Another strength the present study is that the sample size surpassed the number 
needed for a satisfactory EFA. That is, by general consensus, at least 20 times as many 
subjects as variables. In this case, using the PANSS, roughly 600 subjects would be 
required; the present study had a sample consisting of 1429 patients – significantly more 
than twenty subjects per each item of the scale, as generally recommended (Johnson 
and Wichern, 2007) (Hair et al., 1988). 
There is some degree of subjectivity involved in the interpretation of all factor 
analytical processes, especially in EFA (e.g., type of analysis, rotation method and factor 
loading cut-off). Despite these potential limitations, this is the first study to use CFA to 
evaluate comparatively the six-main factor analytical models of PANSS symptoms in TRS 
patients. 
 
4.3) Limitations 
 
One limitation of this study is that patients were classified as having TRS based only 
on clozapine usage. Since clozapine has other indications such as tardive dyskinesia, 
aggressive behavior or reduction of suicide risk (Meltzer et al., 2003), some patients may 
have been incorrectly classified as having TRS.   
Conversely, it is possible that patients not receiving clozapine, and therefore 
defined as NTRS, could be classified as having TRS based on the other criteria, for 
example, failure to respond to two or more trials with non-clozapine antipsychotics, as 
defined in various guidelines and algorithms (Elkis and Buckley, 2016). It is noteworthy 
that 26% of patients in the Pattern study were receiving clozapine. This is roughly as 
expected given the estimated prevalence of TRS in patients with schizophrenia (Elkis, 
2007) (Elkis and Buckley, 2016).  
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The Pattern study was non-interventional and aimed to evaluate the impact of 
symptoms on patient function. Thus, the use of standardized rating scales for treatment 
response and resistance, as currently proposed (Howes et al., 2017), was not the focus 
of the study. As such, we chose a proxy definition of TRS based on the prescription of 
clozapine, an approach used in previous studies (Lally et al., 2016) that has been shown 
to have good specificity (Ajnakina et al., 2018).  
Additionally, although the ideal number of subjects for a PANSS EFA would be 600 
or more (30 variables x 20), our sample of 409 subjects with TRS is satisfactory given it 
has been proposed that a lower limit of 10 subjects per variable (i.e., 300 patients) is 
sufficient to perform an adequate FA (Hair et al., 1988). 
The Pattern study itself has some limitations. Firstly, it was conducted with clinically 
stable patients with chronic schizophrenia attending outpatient clinics. Patients with 
different degrees of severity such as those living in institutions or with minimal 
symptoms were not included, as they do not attend outpatient clinics. Secondly, 
patients who fulfilled recovery criteria were also not included in the study. Thirdly, since 
the inclusion criteria in the Pattern study required informed consent, only adherent 
patients were selected. Finally, interrater reliability was not evaluated. 
In the Pattern study, as in all cross-sectional studies, the findings represent stable 
traits. This feature presents a limitation, as it is known that symptom clusters detectable 
at one time may change during the illness (Haro et al., 2015). Additionally, in our sample 
the frequency of NTRS was four times greater than the frequency of TRS. This difference 
may interfere in the comparison of CFA models. 
It is important to recognize that that about 30% of patients with TRS may be partial 
responders to clozapine (i.e., approximately 10% of the total sample) (Elkis and Buckley, 
2016). These patients are characterized by a predominance of positive symptoms 
(Henna Neto and Elkis, 2007) with a distinct clinical profile when compared to TRS 
patients, thus contributing to the heterogeneity of the TRS sample.  
Finally, it can be argued that the failure to separate patients with TRS from patients 
with NTRS using PANSS factor analysis is due to treatment resistance not representing 
distinct subtypes of schizophrenia, but rather a continuum of illness severity, as 
proposed by Brenner and Merlo (Brenner and Merlo, 1995). 
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There are strong arguments favoring the view that response to treatment 
represents a new paradigm for subtyping schizophrenia (Lee et al., 2015). Recent genetic 
studies, as well as functional and structural neuroimaging research, has found that 
patients with TRS can be distinguished from those who respond to treatment (NTRS) 
based on a series of parameters. These include increased glutamatergic activity in the 
anterior cingulate, a normal dopaminergic activity in the striatum, and significant 
decrease in grey matter as well as a higher familial genetic loading (Gillespie et al., 2017) 
(Demjaha, 2017) (Mouchlianitis et al., 2016) (Jauhar et al., 2017). 
The absence of evidence is not evidence of absence. It is conceivable that since  
clozapine is highly effective for the treatment of most psychopathological dimensions  
of schizophrenia (Elkis and Buckley, 2016) (Siskind et al., 2016), TRS patients in the 
present  
cross-sectional study, who have been treated with clozapine for many years, may  
exhibit a degree of symptom severity similar to those classified as NTRS. Furthermore,  
the PANSS data were collected at different centers across different countries resulting  
in methodological bias due to multiple interviewers and clinical heterogeneity. These  
factors could contribute to the poor model fit and the lack of difference between TRS  
and NTRS groups. 
   Therefore, an ideal study to identify clear differences in the factor structure of the 
PANSS would be a prospective trial based on well-established algorithms for the 
treatment of schizophrenia, such as the International Psychopharmacological Treatment 
Project (IPAP) (www.ipap.org), with an adequate evaluation of treatment response and 
resistance by a valid instrument such as the PANSS, according to the guidelines proposed  
by the TRRIP (Howes et al., 2017) .  
The analysis of factor structure at each time point of such a study would be clinically 
relevant for the identification of underlying psychopathological factors, which could 
represent important predictors of treatment response and resistance.  However, 
Lindenmayer have critically reviewed this aspect, arguing that the failure to replicate a 
common factorial structure of the PANSS lead to development of shorter versions of the 
scale (Lindenmayer, 2017). 
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In fact there were many attempts to reduce the PANSS in order to obtain clusters 
of items which could represent valid and reliable factors to better measure severity of 
illness (Ortiz et al., 2014) or predict treatment response, (Ortiz et al., 2014). Of note is 
the fact Item Response Theory , and not FA, has been proposed as the method of choice 
for such endeavor {Levine, 2011 #454 and a recent study based on this method which 
used  the PANSS-6  (Ostergaard et al., 2018) (composed by  delusions, conceptual 
disorganization, hallucinatory behavior,  blunted affect,  passive/ apathetic social 
withdrawal and lack of spontaneity) proved to be a valid and sensible instrument for the 
evaluation of  severity , remission and efficacy in patients with TRS of phase 2E of the 
CATIE study (McEvoy et al., 2006). 
 
 
5) Conclusions 
 
The present study, which used data of a large sample of patients with schizophrenia 
of the Pattern study, which was conducted in 8 countries, showed a very similar factorial 
structure of the PANSS, when patients with TRS were compared with those with NTRS, 
in terms of exploratory factor analysis. Both analyses yielded a five-factor structure 
whose symptom dimensions could be generally named negative, positive, anxiety-
depression, cognitive and excited. Confirmatory factor analyses showed that, when 
compared with well-established PANSS factor models, both factorial structures showed 
a satisfactory, although not perfect, fit to the data.  
The identification of a specific group of symptoms which could differentiate TRS 
from NTRS would be not only of heuristic but also of clinical importance. Thus, a new 
analysis of the longitudinal data of the Pattern study, which was recently published 
(Haro et al., 2018), based on exploratory and confirmatory models, or by new methods 
such item response theory, may shed light to this important question.  
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